by EPI Health | Sep 20, 2020 | Press Release
Express Scripts National Preferred Formulary covers approximately 24 million lives — Rhofade® is the only FDA-approved alpha 1 agonist indicated for the topical treatment of persistent facial erythema associated with rosacea in adults CHARLESTON,...
by EPI Health | Aug 26, 2020 | Press Release
Collaboration accelerates a Q1 2021 comprehensive launch of MC2’s WYNZORA® Cream to patients with plaque psoriasis in the US WYNZORA® Cream is the first drug based on PADTM Technology - providing innovative solutions to unmet needs in...
by EPI Health | Dec 9, 2019 | Press Release
NEWS PROVIDED BY EPI Health, LLC October 14, 2019, 08:00 ET CHARLESTON, SC, October 14, 2019 /PRNewswire/ — EPI Health, LLC, a specialty pharmaceutical company committed to delivering innovative prescription therapies to dermatologists, today announced...
by EPI Health | Sep 17, 2019 | Press Release
CHARLESTON, SC / ACCESSWIRE / September 17, 2019 / EPI Health, LLC, a specialty pharmaceutical company focused on acquiring, developing and marketing prescription medical dermatological products, today announced the appointment of Brett Fair as Vice President of...
by EPI Health | Oct 2, 2018 | Press Release
HYDERABAD, India & PRINCETON, N.J.-(BUSINESS WIRE)- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today that its wholly owned subsidiary Promius...
by EPI Health | Jul 26, 2017 | Press Release
CHARLESTON, S.C., July 26, 2017 /PRNewswire/ — EPI Health LLC (“EPIH” or the “Company”), a specialty pharmaceutical company wholly owned by EPI Group LLC, announced an agreement with SMG Pharmaceuticals Inc. (“SMG”) to market...
Recent Comments